NASDAQ:CRDF

Cardiff Oncology Stock News

Healthcare > Biotechnology

Buy CRDF

*Your capital is at risk

$1.40

-0.110 (-7.28%)

At Close: Jun 03, 2026

Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC

04:05pm, Tuesday, 17'th Jun 2025

– Veteran executive with over 20 years of oncology leadership and clinical experience with proven track record of success in bringing development candidates through late-stage clinical development

Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025

04:05pm, Monday, 02'nd Jun 2025

– Results from Phase 1b clinical trial evaluating onvansertib + paclitaxel for metastatic triple negative breast cancer demonstrated 40% objective response rate –

Cardiff Oncology (CRDF) Upgraded to Buy: Here's What You Should Know

01:05pm, Wednesday, 14'th May 2025

Cardiff Oncology (CRDF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Cardiff Oncology: Buying The First-Line Onvansertib Strategy

09:05am, Wednesday, 14'th May 2025

Cardiff Oncology's onvansertib shows promise as a first-in-class PLK1 inhibitor for first-line RAS-mutated metastatic colorectal cancer, potentially redefining standard-of-care and achieving blockbust

Cardiff Oncology (CRDF) Reports Q1 Loss, Lags Revenue Estimates

06:25pm, Thursday, 08'th May 2025

Cardiff Oncology (CRDF) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.22 per share a year ago.

Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update

04:05pm, Thursday, 08'th May 2025

- Completed enrollment in randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer (“mCRC”) - - Expanded

Cardiff Oncology: Expecting Massive Updates In Colon Cancer Soon

03:35am, Friday, 02'nd May 2025

Cardiff Oncology's onvansertib shows promising early results in improving response rates for RAS-mutated colorectal cancer, with a critical data update expected by mid-2025. Financially, CRDF has suff

Cardiff Oncology (CRDF) Expected to Beat Earnings Estimates: Should You Buy?

11:09am, Thursday, 24'th Apr 2025

Cardiff Oncology (CRDF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients

04:05pm, Wednesday, 23'rd Apr 2025

The claims cover combination treatment of onvansertib + bev for all bev-naïve patients including RAS-mutated and RAS wild type mCRC across all lines of therapy through 2043 The claims cover combinati

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

04:10pm, Tuesday, 15'th Apr 2025

SAN DIEGO, April 15, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of canc

Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer

04:05pm, Tuesday, 15'th Apr 2025

- Initial results from randomized Phase 2 CRDF-004 trial in RAS-mut mCRC were released in December 2024 - - Additional clinical data from CRDF-004 trial expected in 1H 2025 - SAN DIEGO, April 15, 2025

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by